E. M. Smith

Targeting integrins alpha v beta 3 and alpha v beta 5 for blocking tumor-induced angiogenesis.

B. Neustadt, E. Maxwell, L. Armstrong, 2000, Advances in experimental medicine and biology.

Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist.

B. Neustadt, L. Armstrong, C. Kumar, 2001, Cancer research.

Targeting heat shock protein 72 enhances Hsp90 inhibitor-induced apoptosis in myeloma

G. Morgan, P. Workman, D. Gonzalez, 2010, Leukemia.

Circulating miRNA markers show promise as new prognosticators for multiple myeloma

J. Byrd, A. Palumbo, L. Cascione, 2014, Leukemia.

Preclinical evaluation of 9-chloro-2-methylellipticinium acetate alone and in combination with conventional anticancer drugs for the treatment of human brain tumor xenografts

E. Sausville, W. Alvord, S. Stinson, 1998, Journal of Cancer Research and Clinical Oncology.

Inhibition of Angiogenesis and Tumor Growth by SCH221153, a Dual αvβ3 and αvβ5 Integrin Receptor Antagonist

B. Neustadt, L. Armstrong, C. Kumar, 2001 .